肝动脉插管化疗(transcatheter arterial chemoembolization, TAE)是治疗肝癌的主要非手术方法之一. 但是国内外多项大宗病例分析发现TAE治疗肝癌的效果短暂, 主要原因...
基于4个网页-相关网页
肝动脉插管化疗栓塞 Transcatheter Arterial Chemoembolization ; transarterial chemoembolization
肝动脉插管化疗栓塞术 Transcatheter arterial chemoembolization ; TACE ; trans arterial embolization
经肝动脉插管化疗栓塞 transarterial chemotherapy embolization
肝动脉插管栓塞化疗 Transcatheter Arterial Chemoembolization ; Transcatheter arterial embolization ; transcatheter hepatic anerial chemoembolization ; transarterial chemoembolization
肝动脉内插管化疗栓塞 hepatic arterial embolization ; HAE
肝动脉插管灌注化疗 transcatheter arterial infusion ; TAI
目的观察苦参素与肝动脉插管化疗（TAE）术治疗中晚期肝癌疗效。
Objective: To investigate the effect of Marin solution combined with transcatheter arterial embolization(TAE) on liver cancer .
结论中晚期不能切除的原发性肝癌使用肝动脉、门静脉双重插管灌注化疗，可以改善临床症状、延长存活期。
Conclusion Double intubated hepatic artery and portal vein regional infusion chemotherapy in non-resectable metaphase or late primary liver carcinoma may ameliorate symptoms and prolong survival time.
目的探讨肝动脉、门静脉双重插管区域灌注化疗在中晚期不能切除原发性肝癌应用方法及临床疗效。
Objective To explore the curative effect of double intubated hepatic artery and portal vein regional infusion chemotherapy in non-resectable metaphase or late primary liver carcinoma.
应用推荐